Company profilePharmaceutical#5 of 1,318 in Pakistan2 DRAP alerts

NABIQASIM INDUSTRIES (PVT) LTD.

Pharmaceutical company · 516 brands · 475 molecules

Ranked #6 of 70 companies in Cardiac Care

516 registered products 111 pharmaceutical brands 475 distinct molecules 2 DRAP alerts

Company overview

516
registered products
111
pharmaceutical brands
475
distinct molecules
12
therapeutic classes
2
DRAP alerts

NABIQASIM INDUSTRIES (PVT) LTD. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 516 product registrations across 475 distinct molecules. It is the 5th largest registrant in Pakistan by product count, and ranks 6th of 70 in Cardiac Care. Its portfolio is concentrated in Cardiac Care and Neuro. DRAP has issued 2 alerts involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by NABIQASIM

360 products matched in our catalogue · showing 80 — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

283
ceilings with an approval date
4
not revised in 2+ years
2024
oldest approval year
20244
202555
2026224
Longest without revision

Top molecules by brand count

Empagliflozin17 brands
Clotrimazole13 brands
Amlodipine13 brands
Metformin9 brands
Vaginal8 brands
Telmisartan8 brands
Olanzapine8 brands
Omeprazole7 brands

Therapeutic classes

Cardiac Care · 13Neuro · 13Blood Glucose Lowering Drugs, Excluding Insulin · 11Anti-Infectives · 11Antidepressants · 7Lipid Modifying Agents · 6Antiepileptics · 6Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 6Psycholeptics; Antipsychotics, Anxiolytics, Hypnotics And Sedatives · 5Angiotensin-Ii Antagonists, Combinations · 5Gynaecological Anti-Infective & Antiseptics · 5Antihistamines For Systemic Use · 4

Conditions treated

Hypertension · 7Fungal Infection · 6Anxiety/Depression/Insomnia · 6High Cholestrol · 4General Infections · 4Schizophrenia/Psychosis · 3Oral Agents · 2Muscle Relaxant/Spasm · 2Expectorant · 2Epilepsy/Convulsion · 2Infection/Allergy · 2Angina · 2

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official529 products · Rs 17.26 – Rs 21,190.04
DVAGO64 products · Rs 18.69 – Rs 2,500
Servaid75 products · Rs 58 – Rs 1,350
Median across source: Rs 304.75

Regulatory record

2 alerts in the DRAP feed we track.

SPURIOUS / FALSIFIED MEDICINE DETECTED – DAIZELIVE INJECTION 2ML (DIAZEPAM 10MG/2ML, CLAIM
2025-09-17
Recall Alert: Drug Product; Comycetin 0.5% Eye Drops (Batch # CYF003) by M/S. Nabiqasim In
2023-09-21

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

BIO LABS (PVT) LTD. holds 75 molecules not in this portfolio
000 I.UAprepitantAremetherAzathioprineAzithromycin 250MgBetamethasone 0.1%
GETZ PHARMA PAKISTAN (PVT) LTD. holds 190 molecules not in this portfolio
),Formoterol3 ) 20Mg} Folic AcidAcetazolamideAdrenalineAlbendazoleAmitriptyline
NEUTRO PHARMA (PVT) LTD. holds 74 molecules not in this portfolio
AcetylcysteineAlbendazoleAmikacinAnastrazoleAnastrozoleAntimony

Get the full profile for NABIQASIM

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.